Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy

Paclitaxel has been shown to have clinical activity in the treatment of small cell lung cancer (SCLC). However, its role as third-line chemotherapy for SCLC after both etoposide- and camptothecin-based regimens has not been clarified. All patients with refractory SCLC who were treated with paclitaxe...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore)
Main Authors: Kim, Se Hyun, Kim, Mi-Jung, Kim, Yu Jung, Chang, Hyun, Kim, Jin Won, Lee, Jeong-Ok, Lee, Keun-Wook, Kim, Jee Hyun, Bang, Soo-Mee, Lee, Jong Seok
Format: Artigo
Language:Inglês
Published: Wolters Kluwer Health 2017
Subjects:
5700
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5662365/
https://ncbi.nlm.nih.gov/pubmed/29049199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000008176
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items